RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Developing Botanical Products from India for the US Market

Developing Botanical Products from India for the US Market

Posted 01 August 2009 | By

Botanical or herbal medicine is an age-old practice. Nonetheless, with only 10% of the Earth's estimated 250,000 species of plants considered medicinal, botanicals are the "sleeping giant" of drug development. Indeed, increased side effects of chemical drugs, lack of treatment for several chronic diseases, high cost of new drugs, microbial resistance and emerging diseases are sparking renewed public interest in complementary and alternative medicines.1 The terms "complementary medicine" or "alternative medicine," which are used interchangeably with "traditional medicine" in some countries, refer to a broad set of healthcare practices that are part of a country's tradition and are not integrated into the modern healthcare system.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.